We used a novel approach to address this issue, making use of patients with various inborn errors of immunity impairing most of these cytokine signaling pathways separately to investigate the development of IL-17 T cells in vivo. We studied the following groups: (a) patients with autosomal-dominant developmental disorders associated with various mutations in the TGF-␤ pathway associated with enhanced TGF-␤ signaling, such as Camurati-Engelmann disease, with mutations in TGFB1 ( 14 ) , or Marfan-like syndromes, with mutations in TGFBR1 or TGFBR2 ( 15 ) ; (b) patients with autosomal-recessive susceptibility to pyogenic bacteria and loss-of-function mutations in IRAK4 ( 16 ) or MYD88 (unpublished data), whose cells do not respond to IL-1 ␤ and related cytokines or to Toll-like receptors (TLRs) other than TLR3; (c) patients with autosomaldominant hyper-IgE syndrome (AD-HIES) associated with dominant-negative mutations in STAT3 ( 17, 18 ) , whose cells respond poorly to several cytokines, including IL-6; and (d) patients with autosomal-recessive susceptibility to mycobacterial diseases and loss-of-function mutations in IL12B or IL12RB1 ( 19 ) , whose cells do not express or do not respond to IL-12 and IL-23 (Table S1 , available at http://www.jem.org/cgi/ content/full/jem.20080321/DC1). The role of IL-21 cannot be studied in this way, as the only known defects in this pathway (i.e., JAK3 and common ␥ chain defi ciencies) are typically associated with a total absence of T cells ( 20 ) .
RESULTS AND DISCUSSION
We used fl ow cytometry to investigate the percentage of IL-17 -expressing blood T cells ex vivo in 49 healthy controls. Nonadherent PBMCs were stained for CD3, CD4, CD8, and IL-17. No IL-17 -producing T cells were detected in the absence of activation (unpublished data). Upon activation with PMA-ionomycin, the percentage of CD3-positive cells producing IL-17 ranged from 0.06 to 2% ( Fig. 1, A and B ) . The vast majority ( > 90%) of IL-17 -positive cells were CD4positive and CD8-negative (unpublished data). Thus, within the general population, there is considerable interindividual variability in the numbers of IL-17 -producing cells present among freshly isolated T cells activated ex vivo. This makes it diffi cult to assess the impact of genetic lesions on the development of IL-17 -producing T cells. We tested nine patients with null mutations in IRAK4 or MYD88 , whose cells were unresponsive to IL-1 ␤ (and most TLRs and other IL-1 cytokine family members). The proportion of IL-17 -producing IL-17A (IL-17) is the fi rst of a six-member family of cytokines (IL-17A -F). IL-17 is produced by NK and T cell subsets, including helper ␣ / ␤ T cells, ␥ / ␦ T cells, and NKT cells, and it binds to a widely expressed receptor ( 1 ). This cytokine was fi rst described 10 yr ago, but interest in this molecule was recently revived by the identifi cation of a specifi c IL-17 -producing T helper cell subset in the mouse ( 1 ) . The specifi c development and phenotype of IL-17 -producing helper T cells have been characterized in the mouse model, in which these cells have clearly been identifi ed as a Th17 subset. The hallmarks of mouse Th17 cells include (a) a pattern of cytokine production diff erent from those of the Th1 and Th2 subsets, with high levels of IL-17 production, often accompanied by IL-17F and IL-22; (b) dependence on TGF-␤ and IL-6 for early diff erentiation from naive CD4 T cells, followed by dependence on IL-21 and IL-23 for further expansion; and (c) dependence on at least four transcription factors for diff erentiation: the Th17-specifi c retinoic acid receptor -related orphan receptor ␥ t (ROR ␥ t) and ROR ␣ , and the more promiscuous STAT-3 and IFN regulatory factor 4 (for review see reference 1 ).
Increasingly detailed descriptions of the in vitro and in vivo diff erentiation of the Th17 subset in mice are becoming available. In contrast, the tremendous, uncontrolled genetic and epigenetic variability of human samples has made it diffi cult to characterize human IL-17 -producing T cells ( 2 -13 ) . It has proved very diffi cult to identify the cytokines governing the diff erentiation of these cells in vitro. The fi rst four groups that have investigated this issue all suggested that TGF-␤ was not required for the diff erentiation of human IL-17 -producing T helper cells from purifi ed naive CD4 T cells in vitro ( 5 -8 ) . TGF-␤ was even found to inhibit diff erentiation in three studies ( 5, 6, 8 ) . IL-6 was inhibitory in one study ( 6 ) and redundant in three others ( 5, 7, 8 ) . In contrast, IL-23 was found to enhance the development of IL-17 T cells in all four studies ( 5 -8 ) and IL-1 ␤ was identifi ed as a positive regulator in two studies ( 5, 6 ) , whereas IL-21, which was tested in one study, was found to be redundant ( 8 ) . In contrast, three recent studies showed that TGF-␤ is essential in this process, whereas there was more redundancy between the four ILs ( 11 -13 ) . In vitro studies using recombinant cytokines and blocking antibodies have therefore yielded apparently confl icting results, particularly if the results for human cells are compared with those for mice.
The cytokines controlling the development of human interleukin (IL) 17 -producing T helper cells in vitro have been diffi cult to identify. We addressed the question of the development of human IL-17 -producing T helper cells in vivo by quantifying the production and secretion of IL-17 by fresh T cells ex vivo, and by T cell blasts expanded in vitro from
patients with particular genetic traits affecting transforming growth factor (TGF) ␤ , IL-1, IL-6, or IL-23 responses. Activating mutations in TGFB1 , TGFBR1 , and TGFBR2 (Camurati-Engelmann disease and Marfan-like syndromes) and loss-of-function mutations in IRAK4 and MYD88 (Mendelian predisposition to pyogenic bacterial infections) had no detectable impact. In contrast, dominant-negative mutations in STAT3 (autosomal-dominant hyperimmunoglobulin E syndrome) and, to a lesser extent, null mutations in IL12B and IL12RB1 (Mendelian susceptibility to mycobacterial diseases) impaired the development of IL-17 -producing T cells. These data suggest that IL-12R ␤ 1 -and STAT-3 -dependent signals play a key role in the differentiation and/or expansion of human IL-17 -producing T cell populations in vivo.
We tested 16 patients with AD-HIES bearing mutations in STAT3 . They displayed normal proportions of CCR6-positive CCR4-positive CD4 T cells but low proportions of CCR6positive CCR4-negative CD4 T cells (Table S2 , available at http://www.jem.org/cgi/content/full/jem.20080321/DC1). These patients had signifi cantly fewer IL-17 -positive T cells than controls (P = 9.7 × 10 Ϫ 7 ; Fig. 1, A and B ) . However, as observed in patients with IL-12p40 or IL-12R ␤ 1 defi ciency, some AD-HIES patients had normal proportions of IL-17producing T cells, perhaps refl ecting genetic or epigenetic heterogeneity between individuals, residual STAT-3 signaling, or both. In these experimental conditions, the huge variations in IL-17 secretion between healthy controls (from 50 to 5,000 pg/ml), as measured by ELISA, prevented rigorous comparison with the small number of patients studied (unpublished data). We did not assess other potential features of IL-17 -producing T cells in the patients studied, such as the production of IL-22, a cytokine produced by Th17 cells in mice ( 1 ) and humans ( 5, 6 ) , or expression of ROR ␥ t, a key T cells was not signifi cantly diff erent from that in healthy controls, as shown by Wilcoxon tests comparing the values for each individual between the two groups ( Fig. 1, A and B ). We then tested 17 patients with null mutations in IL12B or IL12RB1 , whose cells did not produce (for IL12B mutations) or did not respond (for IL12RB1 mutations) to IL-23 (and IL-12). Interestingly, there were clearly fewer IL-17 -producing T cells in these patients than in healthy controls (P = 4.7 × 10 Ϫ 3 ; Fig. 1, A and B ). However, some patients had normal numbers of IL-17 -producing T cells. In contrast, cells from patients with mildly enhanced TGF-␤ responses owing to mutations in TGFB1 or TGFBR2 did not diff er significantly from controls ( Fig. 1 B ) . These results suggest that IL-1R -associated kinase 4 (IRAK-4) and MyD88 are not required for the development of IL-17 -producing T cells in vivo, that TGF-␤ probably does not markedly inhibit this process, and that both IL-12p40 and IL-12R ␤ 1 are required, at least in most individuals and in these experimental conditions of fl ow cytometry on T cells activated ex vivo. Table S1 , available at http://www.jem.org/cgi/content/full/jem.20080321/DC1). The percentage indicated in the gate is that of IL-17 -and CD3-positive cells. (B) Percentage of CD3-positive cells that were also IL-17 -positive, as determined by fl ow cytometry of nonadherent PBMCs activated with PMAionomycin. Each symbol represents a value from an individual control (black circles) or patient (red circles). Horizontal bars represent medians. The pvalues for Wilcoxon tests between controls ( n = 49) and patients with mutations in IRAK4 or MYD88 ( n = 9), IL12B or IL12RB1 ( n = 17), TGFB1 or TGFBR2 ( n = 7), and STAT3 ( n = 16) are indicated.
patients bearing specifi c IL-23(R) mutations would be required to rigorously test this hypothesis. We then tested seven patients with mutations associated with mildly enhanced TGF-␤ responses and found no signifi cant diff erences from controls in the four conditions tested ( Fig. 2 ) .
In contrast, 14 patients with mutations in STAT3 had almost no detectable IL-17 -producing T cells in any of the four conditions tested (P = 3.2 × 10 Ϫ 8 , 4.9 × 10 Ϫ 9 , 1.9 × 10 Ϫ 9 , and 3.6 × 10 Ϫ 9 , respectively; Fig. 2 ). This phenotype was clearly more pronounced than that observed with cells from IL-12p40 -and IL-12R ␤ 1 -defi cient patients, as the almost complete lack of IL-17 -positive T cells was not complemented by IL-23, IL-1 ␤ , or a combination of the four cytokines. T cells from the 11 patients with STAT3 mutations studied proliferated normally in these conditions. Our results demonstrate that STAT-3 is required for the expansion of IL-17 -producing T cell blasts, at least in these experimental conditions. In these conditions, all the groups of patients studied had fewer IFN-␥ -producing cells than controls ( Fig. S2 , available at http://www.jem.org/cgi/content/full/jem.20080321/DC1).
Finally, we assessed the secretion of IL-17, IL-22, and IFN-␥ by T cell blasts from controls and patients, with or without activation with PMA-ionomycin, as measured by ELISA ( Fig. 3 ; and Figs. S3 and S4, available at http://www .jem.org/cgi/content/full/jem.20080321/DC1). Control T cell blasts cultured without recombinant cytokine produced detectable amounts of IL-17 in the absence of activation by PMA-ionomycin (mean = 137 ± 149 pg/ml; Fig. 3 A ) . The amounts of IL-17 secreted increased signifi cantly (P = 3 × 10 Ϫ 4 ) upon activation with PMA-ionomycin (mean = 7,338 ± 11,134 pg/ml). However, considerable interindividual variability was observed in both sets of experimental conditions. The addition of IL-23, IL-1 ␤ , or a combination of IL-23, IL-1 ␤ , TGF-␤ , and IL-6 signifi cantly increased the amounts of secreted IL-17 in the absence of activation with PMA-ionomycin (P = 10 Ϫ 4 and 8 × 10 Ϫ 4 , and P < 10 Ϫ 4 , respectively; Fig. 3 , B -D ). Upon PMA-ionomycin activation, only IL-1 ␤ signifi cantly increased the amount of IL-17 secretion (P = 0.04). Four patients with IRAK-4 or MyD88 defi ciency were tested. They displayed low levels of IL-17 secretion in the absence of activation with PMA-ionomycin in the four sets of conditions tested (P = 4 × 10 Ϫ 3 , 10 Ϫ 5 , 10 Ϫ 4 , and 8 × 10 Ϫ 4 , respectively; Fig. 3 ). Upon PMA-ionomycin activation, the level of IL-17 secretion is not signifi cantly diff erent from the controls, except in the presence of IL-1 ␤ (P = 0.04; Fig. 3 ). These results suggest that the Toll/IL-1R signaling pathway, and possibly the IL-1R pathway, may be involved in the secretion of IL-17 in T cell blasts. These patients produced amounts of IL-22 that were similar to the controls (Fig. S3 ).
T cell blasts from the 13 IL-12p40 -or IL-12R ␤ 1 -deficient patients tested secreted normal amounts of IL-17 in the absence of cytokine stimulation ( Fig. 3 A ) . The 10 patients tested produced normal amounts of IL-17 in the presence of IL-1 ␤ ( Fig. 3 C ) . In the presence of the four cytokines, patients with IL-12R ␤ 1 defi ciency did not secrete normal amounts of IL-17 without (P = 2 × 10 Ϫ 3 ) or with (P = 10 Ϫ 3 ) transcription factor in mouse ( 1 ) and human Th17 cells ( 11 ) , as too few blood samples were available. Our results nonetheless suggest that STAT-3 is required for the diff erentiation of human IL-17 -producing T cells in vivo , as suggested by fl ow cytometry analysis on ex vivo -activated T cells. We also assessed the production of IFN-␥ in some patients (Fig. S1 ). The proportion of IFN-␥ -producing T cells was found to be lower in patients with mutations in IRAK4 and MYD88 (P = 1.2 × 10 Ϫ 4 ), IL12RB1 and IL12B (P = 1.8 × 10 Ϫ 3 ), or STAT3 (P = 8 × 10 Ϫ 4 ), but not in patients with mutations in TGFB1 or TGFBR2 (P = 0.11).
No consensus has yet been reached on how to best induce the diff erentiation of human IL-17 T cells from naive CD4 precursors in vitro ( 5 -8, 11 -13 ) , and only small amounts of blood from a limited number of blood samples from our patients were available. We therefore tried to induce specifi c IL-17 memory T cell responses using the cytokines shown to be critical for this lineage in the mouse. We evaluated IL-17 production by populations of T cell blasts expanded in vitro from PBMCs. All patients studied, in particular STAT-3 -defi cient patients, displayed normal proportions of CD4 and CD8 T cells (Table S3 , available at http://www.jem.org/cgi/ content/full/jem.20080321/DC1). We incubated nonadherent PBMCs from controls with OKT3 for 5 d, alone or in the presence of IL-23, IL-1 ␤ , TGF-␤ , or IL-6, or a combination of these four cytokines, and then activated them with PMAionomycin. We did not assess the development of antigenspecifi c IL-17 -producing T cells. There were no IL-17 -positive T cells in any control or in any set of experimental conditions in the absence of activation with PMA-ionomycin, as shown by fl ow cytometry (unpublished data). In the absence of cytokine stimulation, the percentage of IL-17 -positive T cells found in healthy controls after stimulation with PMA-ionomycin was highly variable (from 0.12 to 10%; Fig. 2 A ) . A statistically signifi cant increase in the number of IL-17producing T cells was observed after stimulation with IL-23 (P = 7 × 10 Ϫ 3 ) and IL-1 ␤ (P = 0.04), but not after stimulation with TGF-␤ (P = 0.1) or IL-6 (P = 0.3), as shown by paired t tests ( Fig. 2 and not depicted) . This recall-response pattern is consistent with IL-1 ␤ and IL-23 playing an important role in maintaining and expanding IL-17 T cell populations in mice ( 1 ) and humans ( 11 -13 ) .
We then investigated IL-17 production by T cell blasts from various patients in the same experimental conditions. For four patients with IRAK-4 or MyD88 defi ciency and impaired responses to IL-1 ␤ , the proportion of IL-17 -producing cells appeared to be normal in the various experimental conditions, except in response to IL-1 ␤ ( Fig. 2 ). 16 patients with IL-12p40 ( n = 2) or IL-12R ␤ 1 ( n = 14) defi ciency were found to have much smaller proportions of IL-17 -producing T cells in the absence of cytokine stimulation (P = 7 × 10 Ϫ 5 ; Fig. 2 A ) . The two IL-12p40 -defi cient patients, unlike the IL-12R ␤ 1 -defi cient patients (P = 5 × 10 Ϫ 5 ), apparently responded to IL-23 in these conditions ( Fig. 2 B ) . These data suggest that IL-23 makes a major contribution to the expansion of the IL-17 T cell population in this assay. However, mans ( 25 ) . Impaired IL-6 signaling may be the key factor involved, as suggested by the results obtained for IL-6 -defi cient mice ( 1, 26, 27 ) . However, STAT-3 is also involved in other relevant pathways, including the IL-21 and IL-23 pathways. Our data for IL-12p40 -and IL-12R ␤ 1 -defi cient cells suggest that IL-23 is required for the optimal development of IL-17producing T cells. IL-23 is probably the only cytokine involved, as the patients also lacked IL-12 responses, which might be expected to enhance the development of this subset ( 1 ) . This is consistent with the mouse model, in which IL-23 is required for the maintenance and expansion of these cells ( 1, 28, 29 ) , and with the results of previous human studies based on the use of recombinant cytokines ( 5 -8, 11 -13 ) . In contrast, our fi ndings for IRAK-4 -and MyD88-defi cient cells do not support the notion that IL-1 ␤ (or any of the IL-1Rs and TLRs other than, possibly, TLR3 and TLR4) is essential for the development of human IL-17 -producing T cells ( 5, 6 ), consistent with the phenotype of IL-1 -defi cient mice ( 1 ) . Finally, PMA-ionomycin stimulation ( Fig. 3 D ) . In all culture conditions, cells from patients with IL12B and IL12RB1 mutations secreted less IL-22 than control cells (Fig. S3 ). T cell blasts from all patients with mutations in the TGF-␤ pathway secreted normal amounts of IL-17, whereas T cell blasts from all patients with STAT-3 defi ciency secreted much smaller amounts of IL-17 (P = 8 × 10 Ϫ 6 , 9 × 10 Ϫ 7 , 9 × 10 Ϫ 11 , 2 × 10 Ϫ 7 , 10 Ϫ 8 , 3 × 10 Ϫ 7 , 4 × 10 Ϫ 9 , and 3 × 10 Ϫ 6 , respectively) and IL-22 in all experimental conditions ( Fig. 3 and Fig. S3 ). These data indicate that STAT-3 is required for the maintenance and expansion of IL-17 -secreting human T cell blasts and for the secretion of IL-22 by human T cell blasts, at least in these experimental conditions.
Patients with STAT-3 defi ciency had the most severe IL-17 phenotype of all the patients tested, with a profound impairment of IL-17 production by T cells ex vivo and T cell blasts in vitro. This observation is consistent with fi ndings for STAT-3 -defi cient mice ( 1, 21 -24 ) and a recent report in hu- some present with peripheral candidiasis (unpublished data). Mycobacterial disease is exceedingly rare in STAT-3 -deficient patients, but not in IL-12p40 -and IL-12R ␤ 1 -defi cient patients, in whom it results from impaired IFN-␥ immunity, which is consistent with the redundancy of IL-17 in mouse primary immunity to mycobacteria ( 36, 37 ) . Staphylococcal disease is the main infection seen in STAT-3 -defi cient patients. Mouse IL-17 seems to be involved in immunity to Staphylococcus ( 38 ) . However, both IL-12p40 -and IL-12R ␤ 1 -defi cient patients are normally resistant to Staphylococcus . The function of human IL-17 and related cytokines in host defense therefore remains unknown. The genetic dissection of human infectious diseases should help us to attribute a function to this important cytokine in natura ( 39, 40 ) .
MATERIALS AND METHODS
Patients and controls. 55 healthy, unrelated individuals of various ages from 12 countries (Argentina, Canada, Cuba, France, Germany, Israel, Portugal, Spain, Switzerland, Turkey, UK, and USA) were tested as controls. We also investigated 50 patients with mutations in IRAK4 , MYD88 , IL12B , the paradoxical suggestion that TGF-␤ may have no eff ect or may even inhibit the development of human IL-17 -producing T cells ( 5 -8 ) was neither supported nor disproved by our data for patients with mildly enhanced TGF-␤ responses ( 1 ) .
Does our report provide any clues to the possible function of IL-17 in host defense? The mouse Th17 subset plays a key role in mucosal defense ( 30 ) . IL-23 -and IL-17 -defi cient mice are vulnerable to Klebsiella ( 31, 32 ) . This may account for the greater susceptibility of IL-12p40 -and IL-12R ␤ 1 -defi cient patients than of IFN-␥ R -defi cient patients to both Klebsiella (Levin, M., and S. Pedraza, personal communication; Table S1 ) and the related Salmonella ( 19 ) . However, neither Klebsiella nor Salmonella is commonly found as a pathogen in STAT-3 -defi cient patients despite the apparently greater defect of these patients in terms of IL-17 -producing T cell development ( 17, 18 ) . Mice with impaired IL-17 immunity are also susceptible to Candida ( 33 -35 ) . This may account for the peripheral candidiasis commonly seen in STAT-3 -deficient patients. Interestingly, although most IL-12p40 -and IL-12R ␤ 1 -defi cient patients are not susceptible to Candida ( 19 ), microwell peroxidase substrate (KPL). The reaction was stopped by adding 1.8 M H 2 SO 4 . Optical density was determined with a microplate reader (MRX; Thermolab Systems).
Statistical analysis.
We fi rst assessed diff erences between controls and patients (when there were more than two patients) for (a) the percentage of circulating IL-17 -producing T cells, (b) the percentage of IL-17 -positive T cells in vitro, and (c) the level of IL-17 production in various stimulation conditions, as assessed by ELISA. As the distribution of these three variables could not be assumed to be normal and some of the patient groups examined were very small, we used the nonparametric Wilcoxon exact test, as implemented in the NPAR1WAY module of SAS software (version 9.1; SAS Institute). A second set of tests was performed on controls only to assess the eff ects of diff erent stimulation conditions on (a) the percentage of IL-17 -positive T cells in vitro and (b) the level of IL-17 production, as assessed by ELISA. We used a strategy of matching, with paired t tests performed with the TTEST procedure of SAS software (version 9.1) to investigate the correlation between observations for diff erent controls. For all analyses, P < 0.05 was considered statistically signifi cant.
Online supplemental material. Fig. S1 shows the percentage of CD3positive IFN-␥ -positive cells, as determined by fl ow cytometry of nonadherent PBMCs activated with PMA-ionomycin from controls and patients. Fig. S2 shows intracellular IFN-␥ production in T cell blasts activated with PMA-ionomycin from controls and patients in the various culture conditions, as assessed by fl ow cytometry. Fig. S3 shows the secretion of IL-22 by T cell blasts from controls and patients in the various culture conditions, as measured by ELISA. Fig. S4 shows the secretion of IFN-␥ by T cell blasts from controls and patients in the various culture conditions, as measured by ELISA. Table S1 shows the genetic and clinical features of the patients studied. Table S2 shows the proportions of CCR6-positive CD4 T cells in controls and STAT-3 -defi cient patients. Table S3 shows the proportions of CD4 and CD8 T cells in patients. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20080321/DC1. IL12RB1 , TGFB1 , TGFBR1 , TGFBR2 , or STAT3 (Table S1 ). Our study was conducted in accordance with the Helsinki Declaration, with informed consent obtained from each patient or the patient ' s family, as requested and approved by the institutional review board of the Necker Medical School.
Purifi cation and activation of nonadherent PBMCs. PBMCs were purifi ed by centrifugation on a gradient (Ficoll-Paque PLUS; GE Healthcare) and resuspended in 10% FBS in RPMI (RPMI-10% FBS; Invitrogen). Adherent monocytes were removed by plating PBMCs in a 75-cm 2 horizontal culture fl ask and incubating them for 2 -3 h at 37 ° C in an atmosphere containing 5% CO 2 . The nonadherent cells were washed in RPMI and counted with a counter (Vi-Cell XR; Beckman Coulter). For fl ow cytometry, we distributed 5 × 10 6 cells in 5 ml RPMI-10% FBS in two 25-cm 2 vertical culture fl asks. One fl ask was stimulated with 40 ng/ml PMA (Sigma-Aldrich) and 10 Ϫ 5 M ionomycin (Sigma-Aldrich). All cells were treated with 1 μ l/ml Golgiplug (BD Biosciences), a secretion inhibitor. The fl asks were incubated for 12 h at 37 ° C under an atmosphere containing 5% CO 2 . For ELISA, a 200-μ l aliquot of cells at a concentration of 2.5 × 10 6 cells/ml in RPMI-10% FBS was dispensed into each well of a 96-well plate. The cells were or were not activated with 40 ng/ml PMA and 10 Ϫ 5 M ionomycin. Supernatants were collected after 48 h of incubation at 37 ° C under an atmosphere containing 5% CO 2 .
Expansion and activation of T cell blasts. Nonadherent PBMCs were dispensed into 24-well plates at a density of 2.5 × 10 6 cells/ml in RPMI-10% FBS. All cells were activated with 2 μ g/ml of an antibody against CD3 (Orthoclone OKT3; Janssen-Cilag) alone, or together with 5 ng/ml TGF- Plates were incubated at 37 ° C under an atmosphere containing 5% CO 2 for 3 d. The cells in each well were restimulated using the same activation conditions, except that the antibody against CD3 was replaced by 40 IU/ml IL-2 (Proleukin i.v.; Chiron). 1 ml of each appropriate medium was added, and we gently passed the culture up and down through a pipette to break up clumps. The culture in each well was split in two. Flow cytometry was performed on one of the duplicate wells 2 d later. The cells in this well were stimulated by incubation for 12 h with 40 ng/ml PMA and 10 Ϫ 5 M ionomycin plus 1 μ l/ml Golgiplug at 37 ° C under an atmosphere containing 5% CO 2 . FACS analysis was performed as described in the following section, without extracellular labeling. For ELISA analysis, cultures were allowed to diff erentiate under various conditions for 6 d and were then diluted 1:2 in RPMI-10% FBS supplemented with 40 IU/ml IL-2. 200 μ l of cells in a 96-well plate were activated with 40 ng/ml PMA and 10 Ϫ 5 M ionomycin, or left unactivated. Supernatants were collected after 48 h of incubation at 37 ° C under an atmosphere containing 5% CO 2 .
Flow cytometry. Cells were washed in cold PBS and dispensed into a 96well plate for labeling. Extracellular labeling (for the ex vivo study only) was achieved by incubating the cells with 3 μ l CD3-PECy5 in 50 μ l PBS-2% FBS (BD Biosciences) for 20 min on ice. The cells were washed twice with cold PBS-2% FBS. They were fi xed by incubation with 100 μ l BD Cytofi x (BD Biosciences) for 30 min on ice and washed twice with BD Cytoperm (BD Biosciences), with a 10-min incubation period in BD Cytoperm on ice for the fi rst wash. Cells were then incubated for 1 h on ice with IL-17 -Alexa Fluor 488 (eBioscience) or IFN-␥ -PE (BD Biosciences) at a dilution of 3 μ l of antibody in 50 μ l BD Cytoperm. Cells were washed twice with BD Cytoperm and analyzed with a FACScan machine and CellQuest software (both from Becton Dickinson).
Determination of cytokine levels by ELISA. IL-17, IL-22, and IFN-␥ levels were determined by ELISA. We used the capture antibodies, detection antibodies, and standards supplied in the kits for IL-17 and IL-22 (Duoset; R & D Systems) and in the kit for IFN-␥ (Sanquin), diluted in HPE dilution buff er (Sanquin). Milk was used for blocking, and antibody binding was detected with streptavidin poly -horseradish peroxidase (Sanquin) and TMB
